Researchers have discovered early signs of clinical benefit while testing niraparib, a PARP inhibitor, in patients with advanced melanoma whose tumors had specific genetic changes impacting DNA repair. The single-arm, investigator-initiated phase II trial examined the effectiveness of niraparib in a select group of patients whose disease previously progressed after standard treatment such as immunotherapy, and BRAF/MEK-targeted therapies. The U.S. FDA approved tumor-infiltrating lymphocyte therapy for advanced melanoma in patients who have previously received anti-programmed cell death 1 (PD-1) antibody therapy, and if their tumors are V600 BRAF-mutant, a combination of BRAF and MEK inhibitors. "Despite these available, approved combination...